-
Signature
-
/s/ Mark Tang, attorney-in-fact for Jingye Chen
-
Issuer symbol
-
SE
-
Transactions as of
-
18 Mar 2026
-
Net transactions value
-
-$132,852
-
Form type
-
4
-
Filing time
-
20 Mar 2026, 06:05:39 UTC
Reporting Owners (1)
| Name |
Relationship |
Address |
Signature |
Signature date |
CIK |
| Chen Jingye |
CPO, Shopee |
C/O 1 FUSIONOPOLIS PLACE,, #17-10, GALAXIS, SINGAPORE, SINGAPORE |
/s/ Mark Tang, attorney-in-fact for Jingye Chen |
20 Mar 2026 |
0001965706 |
Transactions Table
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Ownership |
Footnotes |
| transaction |
SE |
Class A ordinary shares |
Sale |
$52,110 |
-614 |
-0.25% |
$84.87 |
240,186 |
18 Mar 2026 |
By BVI entity |
F1, F2 |
| transaction |
SE |
Class A ordinary shares |
Sale |
$14,670 |
-171 |
-0.07% |
$85.79 |
240,015 |
18 Mar 2026 |
By BVI entity |
F1, F3 |
| transaction |
SE |
Class A ordinary shares |
Sale |
$1,298 |
-15 |
-0.01% |
$86.50 |
240,000 |
18 Mar 2026 |
By BVI entity |
F1, F4 |
| transaction |
SE |
Class A ordinary shares |
Sale |
$35,898 |
-445 |
-0.19% |
$80.67 |
239,555 |
19 Mar 2026 |
By BVI entity |
F1, F5 |
| transaction |
SE |
Class A ordinary shares |
Sale |
$26,006 |
-320 |
-0.13% |
$81.27 |
239,235 |
19 Mar 2026 |
By BVI entity |
F1, F6 |
| transaction |
SE |
Class A ordinary shares |
Sale |
$2,870 |
-35 |
-0.01% |
$82.00 |
239,200 |
19 Mar 2026 |
By BVI entity |
F1, F7 |
| holding |
SE |
Class A ordinary shares |
|
|
|
|
|
9,073,908 |
18 Mar 2026 |
Direct |
|
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
Explanation of Responses: